TGF-β Receptor Inhibitor SB431542 Enhanced the Sensitivity of Gastric Cancer to 5-Fluorouracil: New Combined Targeted Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311250 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sara Bonomo und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Fluorouracil, Receptor, Transforming Growth Factor-beta Type I, Benzamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research (MUR).
Abstract (Originalsprache)
Gastric cancer (GC) continues to be a major cause of cancer-related deaths globally, primarily due to resistance to standard treatments like 5-fluorouracil (5FU). The transforming growth factor-β (TGF-β) signaling pathway is recognized as a key contributor to tumor progression and resistance to therapy. This work investigated the therapeutic potential of targeting TGF-β receptor I (TGFBR1) with the selective inhibitor SB431542 to enhance the effect of 5FU in GC. Analysis of public gene expression datasets revealed that increased levels of TGF-β and TGFBR1 are significantly connected with poor prognosis, particularly in high-grade GC. In vitro experiments using AGS and SNU-1 cell lines demonstrated that co-treatment with SB431542 and 5FU significantly reduced cell viability, making GC cells more sensitive to 5FU. This combination treatment led to a significant activation of caspase-dependent apoptosis, indicating an enhanced pro-apoptotic effect. These findings suggest that TGFBR1 inhibition could provide a strategic approach to reduce the dosage of 5FU, thereby minimizing its severe side effects in gastric cancer patients. Furthermore, these results underscore the potential of TGFBR1 as both a prognostic biomarker and a therapeutic target, warranting further investigation in aggressive forms of gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy.
- Department of Biology, University of Pisa, Via Derna 1, 56126 Pisa, Italy.
ORCID-Profile: Roberto Giovannoni, Marialuisa Lavitrano, Massimiliano Cadamuro, Donatella Conconi
Förderung
- Italian Ministry of University and Research (MUR)
Zitieren
APA
Bonomo, S., Giovannoni, R., Lavitrano, M., Cadamuro, M., & Conconi, D. (2025). TGF-β Receptor Inhibitor SB431542 Enhanced the Sensitivity of Gastric Cancer to 5-Fluorouracil: New Combined Targeted Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311250
Vancouver
Bonomo S, Giovannoni R, Lavitrano M, Cadamuro M, Conconi D. TGF-β Receptor Inhibitor SB431542 Enhanced the Sensitivity of Gastric Cancer to 5-Fluorouracil: New Combined Targeted Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311250
BibTeX
@article{Bonomo2025,
author = {Bonomo, Sara and Giovannoni, Roberto and Lavitrano, Marialuisa and Cadamuro, Massimiliano and Conconi, Donatella},
title = {TGF-β Receptor Inhibitor SB431542 Enhanced the Sensitivity of Gastric Cancer to 5-Fluorouracil: New Combined Targeted Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311250}
}
EUVIMED